Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Articles by Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Latest Updated Articles
- The opportunity to evolve the oncology model is ready and waiting
Published: June 1st 2023 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
